Abstract:Liver fibrosis is a chronic pathological process in which the abnormal proliferation of connective tissue is induced by various pathogenic factors. During the process of fibrosis, excessive angiogenesis is observed. Physiological angiogenesis has the potential to impede the progression of liver fibrosis through augmenting matrix metalloenzyme activity; however, pathological angiogenesis can exacerbate liver fibrosis by promoting collagen accumulation. Therefore, a key scientific research focus in the treatment of liver diseases is to search for the "on-off" mechanism that regulates angiogenesis from normal proliferation to pathological proliferation. In this study, we found that excessive angiogenesis appeared during the initial phase of hepatic fibrosis without mesenchymal characteristics. In addition, angiogenesis accompanied by significant endothelial-to-mesenchymal transition (EndMT) was observed in mice after the intraperitoneal injection of angiotensin II (Ang II). Interestingly, the changes in Yes-associated protein (YAP) activity in endothelial cells (ECs) can affect the regulation of angiogenesis by Ang II. The results of in vitro experiments revealed that the regulatory influence of Ang II on ECs was significantly attenuated upon suppression of YAP activity. Furthermore, the function of Ang II in regulating angiogenesis during fibrosis was investigated in liver-specific transgenic mice. The results revealed that Ang II gene deletion could restrain liver fibrosis and EndMT. Meanwhile, Ang II deletion downregulated the profibrotic YAP signaling pathway in ECs. The small molecule AT1R agonist olmesartan targeting Ang II-YAP signaling could also alleviate liver fibrosis. In conclusion, this study identified Ang II as a pivotal regulator of EndMT during the progression of liver fibrosis and evaluated the therapeutic effect of the Ang II-targeted drug olmesartan on liver fibrosis.

Oroxylin A Prevents Angiogenesis of LSECs in Liver Fibrosis Via Inhibition of YAP/HIF‐1α Signaling

ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis

Oroxylin A Prevents Alcohol-Induced Hepatic Steatosis Through Inhibition of Hypoxia Inducible Factor 1Alpha.

Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation

Oroxylin A Inhibits Ethanol‐induced Hepatocyte Senescence Via YAP Pathway

Blockade of Glycolysis-Dependent Contraction by Oroxylin a Via Inhibition of Lactate Dehydrogenase-a in Hepatic Stellate Cells

Oroxylin A, a Classical Natural Product, Shows a Novel Inhibitory Effect on Angiogenesis Induced by Lipopolysaccharide

Oroxyloside Inhibits Angiogenesis Through Suppressing Internalization of VEGFR2/Flk‐1 in Endothelial Cells

Oroxylin a promoted apoptotic extracellular vesicles transfer of glycolytic kinases to remodel immune microenvironment in hepatocellular carcinoma model

Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression

Oroxylin A Induces Apoptosis of Activated Hepatic Stellate Cells Through Endoplasmic Reticulum Stress.

Oroxylin A Suppresses the Development and Growth of Colorectal Cancer Through Reprogram of HIF1α-modulated Fatty Acid Metabolism.

Oroxylin a Attenuates Limb Ischemia by Promoting Angiogenesis via Modulation of Endothelial Cell Migration

Oroxylin A promotes cancer cell-to-macrophage communication and improves immunotherapy in hepatocellular carcinoma model

Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3β signaling in snail-expressing non-small-cell lung cancer cells.

Oroxylin A inhibits hypoxia-induced invasion and migration of MCF-7 cells by suppressing the Notch pathway.

Oroxylin A activates ferritinophagy to induce hepatic stellate cell senescence against hepatic fibrosis by regulating cGAS-STING pathway

Oroxylin A Sensitizes Non-Small Cell Lung Cancer Cells to Anoikis Via Glucose-Deprivation-like Mechanisms: C-Src and Hexokinase II.

Oroxylin A Inhibits Matrix Metalloproteinase-2/9 Expression and Activation by Up-Regulating Tissue Inhibitor of Metalloproteinase-2 and Suppressing the ERK1/2 Signaling Pathway

Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells.

Angiotensin II depends on hippo/YAP signaling to reprogram angiogenesis and promote liver fibrosis